Clinical trial GRAVITAS-309
A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
| Cancers | |
|---|---|
| Organ | NA |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2/3 |
| Academic trial | Non |
| Sponsor | Incyte Corporate |
| EudraCT Identifier | 2018-001606-29 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03584516 |
| Inclusion criteria | 1. moderate or severe cGVHD per NIH Consensus Criteria2. KPS score > 60%.3. Evidence of myeloid and platelet engraftment, that is, ANC > 1.0 × 10e9/L and plateletcount > 50 × 10e9/L.4. Has not received more than 3 days/72 hours of systemic corticoster |
| Last update |